Molina Healthcare is absorbing roughly $2.50 per diluted share this year from two simultaneous strategic moves. The scale of that cost shows in the company’s Q3 2026 results. It says more about where the managed care market is heading than the headline figures do.
The Long Beach, California-based insurer reported Q3 GAAP net income of $38 million, or $0.73 per diluted share, down 52% from a year earlier. Adjusted net income was $46 million, or $0.89 per diluted share. Full-year GAAP guidance stands at $2.38 per diluted share.
That guidance figure contains two discrete items totaling $2.50 per share. One is a $1.00 per-share loss from exiting its traditional Medicare Advantage prescription drug (MAPD) product. The other is a $1.50 per-share drag from launching a new Florida Medicaid contract in Q4 2026. Without those two charges, the underlying business is tracking closer to $4.88 GAAP EPS.
The MAPD exit, announced in February 2026, reflects a deliberate strategic narrowing. Molina is walking away from the traditional Medicare Advantage drug business and refocusing its Medicare segment exclusively on dual-eligible members. The company took a $93 million impairment charge in the first half of 2026 related to the decision.
Medicare membership has fallen from 262,000 at the end of 2025 to 222,000 in Q3, a 15% drop in nine months. The Medicare MCR improved slightly to 93.0% in Q3 from 93.6% a year earlier. Molina’s pivot toward dual-eligible plans follows a pattern across the broader Medicare Advantage market. Carriers have been expanding their special needs plan footprints while cutting standard PPO and MAPD offerings, a trend Humana and UnitedHealthcare have both accelerated heading into 2027.
The Florida Medicaid contract is expected to go live in Q4. It carries an upfront loss that Molina has been transparent about, and reflects a trade-off common in Medicaid managed care. Contracts typically run three to five years with renewal options, so the Q4 loss is the entry cost for a long-term revenue commitment.
Membership in Molina’s ACA Marketplace segment has dropped from 655,000 at the end of 2025 to 267,000 in Q3 2026, a 59.2% decline in nine months. Premium revenue from the segment fell 46% year over year to $642 million.
Molina raised average Marketplace premiums 30% for 2026, a deliberate move to reduce its footprint. CEO Joseph Zubretsky said during Q2 the company aims to cut marketplace revenue by approximately $1 billion in 2027. Molina plans to concentrate in around six states.
That retreat is running alongside a broader market contraction. National individual health insurance enrollment fell 18% between June 2025 and June 2026, according to a KFF analysis of individual market enrollment published in October 2026. The decline was driven largely by the expiration of enhanced ACA subsidies at the end of 2025. Advisors placing clients in Marketplace plans are navigating a shrinking field of available Molina options ahead of 2027 open enrollment, which opens November 1.
The Marketplace MCR improved to 92.5% in Q3 from 95.6% a year earlier. Losing lower-margin members while retaining a smaller book at higher price points improved the ratio, even as total revenue declined sharply.
Molina’s Medicaid segment produced $8.2 billion in Q3 premium revenue, up 2.3% year over year, with rate updates absorbing a membership decline from 4.6 million a year ago to 4.4 million. The Medicaid MCR was 93.0%, up from 92.0% a year earlier.
Zubretsky said on the Q3 call the company believes it is observing the beginning of a turn in Medicaid margins, citing a plateauing of medical cost trend. Stronger 2027 rate updates are part of his case. The Q3 Medicaid MCR deteriorated year over year, so that turn remains a forward-looking call rather than a reported outcome.
Full-year premium revenue guidance is unchanged at approximately $42 billion. Operating cash flow for the nine months ended September 30 was $629 million, reversing a $237 million outflow in the same period of 2025.
